Increased mortality after total hip prosthetic joint infection is mainly caused by the comorbidities rather than the infection itself
DOI:
https://doi.org/10.2340/17453674.2023.18619Keywords:
Arthroplasty, Hip, Implants, InfectionAbstract
Background and purpose: Periprosthetic joint infection (PJI) is a feared complication of arthroplasty surgery. There is controversy as to whether PJI also correlates with increased mortality. Our aim was to investigate in a nationwide cohort if PJI is an independent risk factor for dying.
Patients and methods: We performed a retrospective cohort study based on data from the Swedish Hip Arthroplasty Register (SHAR). All patients with a revision THA performed between 1998 and 2017 were included. The outcome is mortality; exposure is PJI according to SHAR. The control group was study participants who underwent aseptic revision. Confounders were age, sex, diagnosis, and comorbidity according to the Elixhauser index. The outcome was analyzed with a Cox proportional hazards model.
Results: 4,943 PJI revisions and 12,529 non-infected revisions were included in the analysis. The median follow-up time was 4.1 years. In the PJI group, 1,972 patients died and in the control group, 4,512. The incidence rate ratio was 1.19 (95% confidence interval [CI] 1.13–1.25), the crude hazard ratio (HR) 1.19 (CI 1.13–1.25), and the adjusted HR 1.05 (CI 0.99–1.12) for the exposed versus the unexposed group. The strongest confounder was comorbidity.
Conclusion: The increased mortality risk after revision due to PJI is mainly caused by the comorbidity of the patient, rather than by the infection itself.
Downloads
References
Gundtoft P H, Overgaard S, Schønheyder H C, Møller J K, Kjærsgaard-Andersen P, Pedersen A B. The “true” incidence of surgically treated deep prosthetic joint infection after 32,896 primary total hip arthroplasties: a prospective cohort study. Acta Orthop 2015; 86(3): 326-34. doi: 10.3109/17453674.2015.1011983. DOI: https://doi.org/10.3109/17453674.2015.1011983
Lindgren J V, Gordon M, Wretenberg P, Kärrholm J, Garellick G. Validation of reoperations due to infection in the Swedish Hip Arthroplasty Register. BMC Musculoskelet Disord 2014; 15: 384. doi: 10.1186/1471-2474-15-384. DOI: https://doi.org/10.1186/1471-2474-15-384
Dale H, Fenstad A M, Hallan G, Overgaard S, Pedersen A B, Hailer N P, et al. Increasing risk of revision due to infection after primary total hip arthroplasty: results from the Nordic Arthroplasty Register Association. Acta Orthop 2023; 94: 307-15. doi: 10.2340/17453674.2023.13648. DOI: https://doi.org/10.2340/17453674.2023.13648
Kapadia B H, Berg R A, Daley J A, Fritz J, Bhave A, Mont M A. Periprosthetic joint infection. Lancet 2016; 387(10016): 386-94. doi: 10.1016/s0140-6736(14)61798-0. DOI: https://doi.org/10.1016/S0140-6736(14)61798-0
Klouche S, Sariali E, Mamoudy P. Total hip arthroplasty revision due to infection: a cost analysis approach. Orthop Traumatol Surg Res OTSR 2010; 96(2): 124-32. doi: 10.1016/j.rcot.2010.02.005. DOI: https://doi.org/10.1016/j.otsr.2009.11.004
Kurtz S M, Lau E, Watson H, Schmier J K, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 2012; 27(8 Suppl.): 61-5.e1. doi: 10.1016/j.arth.2012.02.022. DOI: https://doi.org/10.1016/j.arth.2012.02.022
Bozic K J, Katz P, Cisternas M, Ono L, Ries M D, Showstack J. Hospital resource utilization for primary and revision total hip arthroplasty. J Bone Joint Surg Am 2005; 87(3): 570-6. doi: 10.2106/jbjs.D.02121. DOI: https://doi.org/10.2106/JBJS.D.02121
Zmistowski B, Karam J A, Durinka J B, Casper D S, Parvizi J. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am 2013; 95(24): 2177-84. doi: 10.2106/jbjs.L.00789. DOI: https://doi.org/10.2106/JBJS.L.00789
Shahi A, Tan T L, Chen A F, Maltenfort M G, Parvizi J. In-hospital mortality in patients with periprosthetic joint infection. J Arthroplasty 2017; 32(3): 948-52.e1. doi: 10.1016/j.arth.2016.09.027. DOI: https://doi.org/10.1016/j.arth.2016.09.027
Choi H R, Bedair H. Mortality following revision total knee arthroplasty: a matched cohort study of septic versus aseptic revisions. J Arthroplasty 2014; 29(6): 1216-18. doi: 10.1016/j.arth.2013.11.026. DOI: https://doi.org/10.1016/j.arth.2013.11.026
Choi H R, Beecher B, Bedair H. Mortality after septic versus aseptic revision total hip arthroplasty: a matched-cohort study. J Arthroplasty 2013; 28(8 Suppl.): 56-8. doi: 10.1016/j.arth.2013.02.041. DOI: https://doi.org/10.1016/j.arth.2013.02.041
Blumenfeld T J. Does the infection or the treatment kill the patient?: Commentary on an article by Zmistowski B S, et al.: :Periprosthetic joint infection increases the risk of one-year mortality:. J Bone Joint Surg Am 2013; 95(24): e200(1-2). doi: 10.2106/jbjs.M.01085. DOI: https://doi.org/10.2106/JBJS.M.01085
Garellick G K J, Lindahl H, Malchau H, Rogmark C, Rolfson O. The Swedish Hip Arthroplasty Register Annual Report 2014; 2015. Available from: http://www.shpr.se/Libraries/Documents/Arsrapport_2014_WEB.sflb.ashx.
National Patient Register [Internet]; 2019. Available from: https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-national-patient-register/.
Cause of Death Register 2022; 2022. Available from: https://www.socialstyrelsen.se/statistik-och-data/register/dodsorsaksregistret/.
Annual Report—The Swedish Arthroplasty Register; 2023.
Elixhauser A, Steiner C, Harris D R, Coffey R M. Comorbidity measures for use with administrative data. Med Care 1998; 36(1): 8-27. doi: 10.1097/00005650-199801000-00004. DOI: https://doi.org/10.1097/00005650-199801000-00004
VanderWeele T J. Mediation analysis: a practitioner’s guide. Annu Rev Public Health 2016; 37: 17-32. doi: 10.1146/annurev-publ-health-032315-021402. DOI: https://doi.org/10.1146/annurev-publhealth-032315-021402
MacKinnon D P, Krull J L, Lockwood C M. Equivalence of the mediation, confounding and suppression effect. Prev Sci 2000; 1(4): 173-81. doi: 10.1023/a:1026595011371. DOI: https://doi.org/10.1023/A:1026595011371
Gundtoft P H, Pedersen A B, Varnum C, Overgaard S. Increased mortality after prosthetic joint infection in primary THA. Clin Orthop Relat Res 2017; 475(11): 2623-31. doi: 10.1007/s11999-017-5289-6. DOI: https://doi.org/10.1007/s11999-017-5289-6
Charlson M E, Pompei P, Ales K L, MacKenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373-83. doi: 10.1016/00219681(87)90171-8. DOI: https://doi.org/10.1016/0021-9681(87)90171-8
Menendez M E, Neuhaus V, van Dijk C N, Ring D. The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res 2014; 472(9): 2878-86. doi: 10.1007/s11999-014-3686-7. DOI: https://doi.org/10.1007/s11999-014-3686-7
Natsuhara K M, Shelton T J, Meehan J P, Lum Z C. Mortality during total hip periprosthetic joint infection. J Arthroplasty 2019; 34(7s): S337-s42. doi: 10.1016/j.arth.2018.12.024. DOI: https://doi.org/10.1016/j.arth.2018.12.024
Lamb J N, Nix O, Al-Wizni A, West R, Pandit H. Mortality after postoperative periprosthetic fracture of the femur after hip arthroplasty in the last decade: meta-analysis of 35 cohort studies including 4841 patients. J Arthroplasty 2022; 37(2): 398-405.e1. doi: 10.1016/j.arth.2021.09.006. DOI: https://doi.org/10.1016/j.arth.2021.09.006
Khan T, Middleton R, Alvand A, Manktelow A R J, Scammell B E, Ollivere B J. High mortality following revision hip arthroplasty for periprosthetic femoral fracture. Bone Joint J 2020; 102-b(12): 1670-4. doi: 10.1302/0301-620x.102b12.Bjj-2020-0367.R1. DOI: https://doi.org/10.1302/0301-620X.102B12.BJJ-2020-0367.R1
Laughlin M S, Vidal E A, Drtil A A, Goytia R N, Mathews V, Patel A R. Mortality after revision total hip arthroplasty. J Arthroplasty 2021; 36(7): 2353-8. doi: 10.1016/j.arth.2021.01.022. DOI: https://doi.org/10.1016/j.arth.2021.01.022
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Anders Persson, Olof Sköldenberg, Maziar Mohaddes, Thomas Eisler, Max Gordon
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
